ioana berindan neagoe
ioana berindan neagoe
The Oncology Institute Ion Chiricuta University of Medicine and Pharmacy Iuliu Hatieganu Cluj Napoca
Verifierad e-postadress på umfcluj.ro
Titel
Citeras av
Citeras av
År
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer
H Ling, R Spizzo, Y Atlasi, M Nicoloso, M Shimizu, RS Redis, N Nishida, ...
Genome research 23 (9), 1446-1461, 2013
4732013
MicroRNAome genome: a treasure for cancer diagnosis and therapy
I Berindan‐Neagoe, PC Monroig, B Pasculli, GA Calin
CA: a cancer journal for clinicians 64 (5), 311-336, 2014
3652014
Apoptosis in cancer: key molecular signaling pathways and therapy targets
C Burz, I Berindan-Neagoe, O Balacescu, A Irimie
Acta oncologica 48 (6), 811-821, 2009
2442009
Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells
D Arango, AJ Wilson, Q Shi, GA Corner, MJ Aranes, C Nicholas, M Lesser, ...
British journal of cancer 91 (11), 1931-1946, 2004
2382004
Junk DNA and the long non-coding RNA twist in cancer genetics
H Ling, K Vincent, M Pichler, R Fodde, I Berindan-Neagoe, FJ Slack, ...
Oncogene 34 (39), 5003-5011, 2015
2372015
Exosomes as divine messengers: are they the Hermes of modern molecular oncology?
C Braicu, C Tomuleasa, P Monroig, A Cucuianu, I Berindan-Neagoe, ...
Cell Death & Differentiation 22 (1), 34-45, 2015
2012015
CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations
RS Redis, AM Sieuwerts, MP Look, O Tudoran, C Ivan, R Spizzo, X Zhang, ...
Oncotarget 4 (10), 1748, 2013
1642013
Progresses towards safe and efficient gene therapy vectors
S Chira, CS Jackson, I Oprea, F Ozturk, MS Pepper, I Diaconu, C Braicu, ...
Oncotarget 6 (31), 30675, 2015
1572015
Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease
CS Cătană, IB Neagoe, V Cozma, C Magdaş, F Tăbăran, DL Dumitraşcu
World Journal of Gastroenterology: WJG 21 (19), 5823, 2015
1532015
The relationship between the structure and biological actions of green tea catechins
C Braicu, MR Ladomery, VS Chedea, A Irimie, I Berindan-Neagoe
Food Chemistry 141 (3), 3282-3289, 2013
1162013
Allele-specific reprogramming of cancer metabolism by the long non-coding RNA CCAT2
RS Redis, LE Vela, W Lu, JF de Oliveira, C Ivan, C Rodriguez-Aguayo, ...
Molecular cell 61 (4), 520-534, 2016
1072016
The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis
H Ling, K Pickard, C Ivan, C Isella, M Ikuo, R Mitter, R Spizzo, MD Bullock, ...
Gut 65 (6), 977-989, 2016
1042016
Gold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cells.
C Tomuleasa, O Soritau, A Orza, M Dudea, B Petrushev, O Mosteanu, ...
Journal of Gastrointestinal & Liver Diseases 21 (2), 2012
962012
Molecular pathways: microRNAs, cancer cells, and microenvironment
I Berindan-Neagoe, GA Calin
Clinical cancer research 20 (24), 6247-6253, 2014
872014
Clinical and pathological implications of miRNA in bladder cancer
C Braicu, R Cojocneanu-Petric, S Chira, A Truta, A Floares, B Petrut, ...
International journal of nanomedicine 10, 791, 2015
812015
Epigallocatechin-3-Gallate (EGCG) inhibits cell proliferation and migratory behaviour of triple negative breast cancer cells
C Braicu, CD Gherman, A Irimie, I Berindan-Neagoe
Journal of Nanoscience and Nanotechnology 13 (1), 632-637, 2013
742013
Combining anti-miR-155 with chemotherapy for the treatment of lung cancers
K Van Roosbroeck, F Fanini, T Setoyama, C Ivan, C Rodriguez-Aguayo, ...
Clinical Cancer Research 23 (11), 2891-2904, 2017
732017
Electrochemical immunosensors in breast and ovarian cancer
I Diaconu, C Cristea, V Hârceagă, G Marrazza, I Berindan-Neagoe, ...
Clinica Chimica Acta 425, 128-138, 2013
732013
CRISPR/Cas9: transcending the reality of genome editing
S Chira, D Gulei, A Hajitou, AA Zimta, P Cordelier, I Berindan-Neagoe
Molecular Therapy-Nucleic Acids 7, 211-222, 2017
712017
The new era of nanotechnology, an alternative to change cancer treatment
A Jurj, C Braicu, LA Pop, C Tomuleasa, CD Gherman, I Berindan-Neagoe
Drug design, development and therapy 11, 2871, 2017
682017
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20